Based on the associations of CD103+ TRMs with metastases and survival in different types of cancer, it remains unclear how CD103+ TRMs influences outcome in different cancers and whether the pathogenic role of CD103+ TRMs in diverse cancer types is tumor or organ-dependent, or differs between primary and metastatic tumors in some cancer types. This evidence concerns the gene ITGAE and metastatic neoplasm.